Javid Moslehi

In the first large-scale analysis of cardiovascular complications linked to immune checkpoint inhibitors, Vanderbilt researchers have identified several of the conditions that arise and have determined that they usually appear early in treatment. Read More

Vanderbilt University Medical Center investigators have identified a growing number of serious and sometimes fatal cases of heart problems among cancer patients treated with some forms of immunotherapy. Read More

People who have dealt with cancer may also need to take special care of their hearts. Here’s how. Read More

Justin Balko, Pharm.D., Ph.D., seated, Javid Moslehi, M.D., left, and Douglas Johnson, M.D., MSCI, review data on rare cardiac side effects linked to cancer immunotherapy combination therapy. (photo by Susan Urmy) Combination therapy using two approved immunotherapy drugs for cancer treatment may cause rare and sometimes fatal cardiac side… Read More

Improved therapies have led to a spike in the number of people living with cancer, and today there are more than 15.5 million survivors in the United States. However, some of these therapies can cause toxicities to the heart, the vessels and the body’s metabolism. Read More

The 3 million prostate cancer survivors in the United States are likely to die from something other than cancer, thanks to early detection, effective treatment and the disease’s slow progression. Read More

Vanderbilt is embarking on a multi-disciplinary approach to understand how promising cancer treatments, specifically certain kinase inhibitors, affect the heart and kidneys. Read More

The Vanderbilt Cardio-Oncology program has fostered a collaborative relationship combining the expertise of cardiologists and oncologists to understand effects of cancer therapy on the heart. Read More

The Vanderbilt Cardio-Oncology program has fostered a special collaborative relationship combining the expertise of cardiologists and oncologists to understand the effects of cancer therapy on the heart. This type of collaboration is now helping to define the cardiovascular health of more than 14 million cancer survivors in the United States. Read More